By integrating network pharmacology, molecular docking, and rigorous in vitro and in vivo validation, we provide compelling preclinical evidence that CDN suppresses the JAK/STAT3 signaling axis, thereby inhibiting CRC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). This evidence concerns the gene STAT3 and colorectal carcinoma.